Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal...

Area of Science:

• Nephrology
• Pharmacology
• Toxicology

Background:

• Amphotericin B (AmB) is an antifungal agent known to cause nephrotoxicity.
• AmB-induced nephrotoxicity in rats is characterized by polyuria, polydipsia, and tubular damage.
• Renal insufficiency in rats is exacerbated by restricted water intake, highlighting the importance of hydration.

Purpose of the Study:

• To investigate the efficacy of vigorous hydration in preventing Amphotericin B-induced nephrotoxicity in patients with hematologic malignancies.
• To monitor renal tubular function and electrolyte balance in patients receiving AmB therapy with aggressive hydration protocols.

Main Methods:

• A clinical study involving 61 patients with hematologic malignancies undergoing AmB therapy.
• Massive hydration protocol to achieve urine output of ≥4000 mL/day.
• Monitoring of urine electrolytes (sodium, potassium, magnesium) and serum creatinine clearance; supplementation of lost ions.

Main Results:

• Patients receiving AmB therapy showed signs of renal tubular damage, indicated by increased fractional excretion of sodium and potassium.
• Significant ion supplementation (potassium, magnesium) was required to correct electrolyte losses.
• Serum ion concentrations and creatinine clearance remained stable throughout the treatment period.
• No patients required premature cessation of AmB treatment due to clinically significant renal damage.

Conclusions:

• Vigorous hydration is a critical strategy for mitigating Amphotericin B-induced nephrotoxicity in clinical settings.
• Aggressive fluid management and electrolyte supplementation can preserve renal function during AmB therapy.
• This approach allows for the continued use of AmB in patients with hematologic malignancies without compromising kidney health.